Gene-edited iPSC: the role of Automation in Cell Line Development

Introduction 

The development of cell-based therapies, particularly allogeneic approaches, relies heavily on precise gene editing to enhance cell function, improve persistence, and reduce immunogenicity. In practice, this means that developers combine multiple gene knockouts with multiple gene knock-ins, resulting in an average of six to eight different gene edits. However, manual genome editing processes suffer from limitations in scalability, efficiency, and standardization. Achieving this level of complexity requires robust platforms that can execute and validate multiple gene modifications with high efficiency and reliability.